BACKGROUND: De novo posttransplant malignancy (PTM) is a serious complication of transplantation. Incidences may vary among solid organ transplantations (SOTs) and may take to particular screening recommendations and posttransplantation care. METHODS: Adult recipients, from the U.S. Organ Procurement Transplant Network/United Network for Organ Sharing database (data as of September 3, 2010), of a primary kidney transplantation (KT), liver transplantation (LT), heart transplantation (HT) or lung transplantation (LuT) performed in the United States between 1999 and 2008 were selected. Multiple-organ recipients and those whose grafts failed within 2 weeks after transplantation were excluded. The incidence of PTM (in 1000 person-years) was estimated using the Kaplan-Meier product-limit method and compared with SOT and the general population. RESULTS: The cohort included 193,905 recipients (123,380 KT; 43,106 LT; 16511 HT; and 10,908 LuT). PTM incidence was 8.03, 11.0, 14.3, and 19.8 in KT, LT, HT, and LuT, respectively. In general, PTM recipients were 3 to 5 years older, mostly whites, and are males in all SOTs. In KT, the type of cancer with the highest incidence was posttransplant lymphoproliferative disorder (PTLD, 1.58%), followed by lung (1.12%), prostate (0.82%), and kidney (0.79%) cancers; in LT, PTLD (2.44%), lung and bronchial (2.18%), primary hepatic (0.91%), and prostate (0.88%) cancers; in HT, lung and bronchial (3.24%) and prostate (3.07%) cancers, and PTLD (2.24%); and in LuT, lung and bronchial cancers (5.94%), PTLD (5.72%), and colorectal cancer (1.38%). PTLD, Kaposi sarcoma, and lung and bronchial cancers were increased in all SOTs, when compared with an older (55- to 59-year-old) population. CONCLUSIONS: Cancer incidence is different among solid organ transplantations, and ratios may be higher than those in the 55- to 59-year-old population.
BACKGROUND: De novo posttransplant malignancy (PTM) is a serious complication of transplantation. Incidences may vary among solid organ transplantations (SOTs) and may take to particular screening recommendations and posttransplantation care. METHODS: Adult recipients, from the U.S. Organ Procurement Transplant Network/United Network for Organ Sharing database (data as of September 3, 2010), of a primary kidney transplantation (KT), liver transplantation (LT), heart transplantation (HT) or lung transplantation (LuT) performed in the United States between 1999 and 2008 were selected. Multiple-organ recipients and those whose grafts failed within 2 weeks after transplantation were excluded. The incidence of PTM (in 1000 person-years) was estimated using the Kaplan-Meier product-limit method and compared with SOT and the general population. RESULTS: The cohort included 193,905 recipients (123,380 KT; 43,106 LT; 16511 HT; and 10,908 LuT). PTM incidence was 8.03, 11.0, 14.3, and 19.8 in KT, LT, HT, and LuT, respectively. In general, PTM recipients were 3 to 5 years older, mostly whites, and are males in all SOTs. In KT, the type of cancer with the highest incidence was posttransplant lymphoproliferative disorder (PTLD, 1.58%), followed by lung (1.12%), prostate (0.82%), and kidney (0.79%) cancers; in LT, PTLD (2.44%), lung and bronchial (2.18%), primary hepatic (0.91%), and prostate (0.88%) cancers; in HT, lung and bronchial (3.24%) and prostate (3.07%) cancers, and PTLD (2.24%); and in LuT, lung and bronchial cancers (5.94%), PTLD (5.72%), and colorectal cancer (1.38%). PTLD, Kaposi sarcoma, and lung and bronchial cancers were increased in all SOTs, when compared with an older (55- to 59-year-old) population. CONCLUSIONS:Cancer incidence is different among solid organ transplantations, and ratios may be higher than those in the 55- to 59-year-old population.
Authors: Sara A Mansfield; Stanislaw P A Stawicki; Rachel C Forbes; Thomas J Papadimos; David E Lindsey Journal: J Gastrointestin Liver Dis Date: 2013-12 Impact factor: 2.008
Authors: Jesse Cheng; Cody A Moore; Carlo J Iasella; Allan R Glanville; Matthew R Morrell; Randall B Smith; John F McDyer; Christopher R Ensor Journal: Clin Transplant Date: 2018-03-30 Impact factor: 2.863
Authors: Sophie Caillard; Etienne Cellot; Jacques Dantal; Olivier Thaunat; François Provot; Bénédicte Janbon; Matthias Buchler; Dany Anglicheau; Pierre Merville; Philippe Lang; Luc Frimat; Charlotte Colosio; Eric Alamartine; Nassim Kamar; Anne Elisabeth Heng; Antoine Durrbach; Valérie Moal; Joseph Rivalan; Isabelle Etienne; Marie Noelle Peraldi; Anne Moreau; Bruno Moulin Journal: Clin J Am Soc Nephrol Date: 2017-08-17 Impact factor: 8.237